marijuana stocks news

Cara Therapeutics Inc. (CARA)

 

 

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Total Revenue 914   1,125   960   178  
Cost of Revenue
Gross Profit 914   1,125   960   178  
Operating Expenses
Research Development 3,459 6,208 3,200 2,201
Selling General and Administrative 1,791 1,520 1,472 1,398
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss (4,336) (6,603) (3,712) (3,421)
Income from Continuing Operations
Total Other Income/Expenses Net
Earnings Before Interest And Taxes (4,314) (6,577) (3,656) (3,399)
Interest Expense
Income Before Tax (4,314) (6,577) (3,656) (3,399)
Income Tax Expense (142) (32) (11) (16)
Minority Interest
Net Income From Continuing Ops (4,172) (6,545) (3,645) (3,383)
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (4,172) (6,545) (3,645) (3,383)
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares (4,172) (6,545) (3,645) (3,383)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Tauriga Sciences, Inc. (TAUG) Showcases its Graphic Design and Artwork for the Individual Pack of its CBD Infused Gum

Tauriga Sciences Inc. Showcases its Graphic Design and Artwork for the Individual…

 AeroGrow International, Inc. (AERO) Reports 3rd Quarter Results

AeroGrow Reports 3rd Quarter Results  AeroGrow International, Inc. (OTCQB: AERO) (“AeroGrow” or…

Tetra Bio-Pharma Inc. (TBPMF) Receives Favorable Letter of Advice from USA FDA for QIXLEEF

Tetra Bio-Pharma Receives Favorable Letter of Advice from USA FDA for QIXLEEF…